Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Russian Journal of Pediatric Hematology and OncologyOpen Access

Treatment of children with relapsed and refractory classical Hodgkin’s lymphoma: the experience of two centers

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNatalia S. TsaplinaRussian Cancer Research Center NN BlokhinАКА. В. КозловFirst Pavlov State Medical University of St. PetersburgТВТ. Т. ВалиевMinistry of Health

Discussion

Loading...

Member takes

Overview

Analysis reports significant survival rates in children treated for relapsed and refractory lymphoma, suggesting brentuximab vedotin enhances outcomes.

Key Points

  • The 10-year overall survival rate was 76%, indicating effective treatment strategies for relapsed and refractory classical Hodgkin lymphoma.
  • Inclusion of brentuximab vedotin resulted in a higher relapse-free survival rate of 83%, emphasizing its potential role in therapy.
  • Seventy-three patients aged 5.5 to 18.6 years were included in this study, providing insights into treatment effectiveness across a pediatric population.
  • This cooperative effort between two Russian clinics demonstrates the importance of targeted therapies and stem cell transplantation in improving patient outcomes.

Cite This Study

Tsaplina et al. (2024) studied this question.

synapsesocial.com/papers/68c1dda954b1d3bfb60fc8dbhttps://doi.org/10.21682/2311-1267-2024-11-3-22-29
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma2022 · 171 citations
  2. 2The experience of using the Brentuximab vedotin in the treatment of children and young adults with primary refractory course and relapses of Hodgkin's lymphoma2020 · 4 citations
  3. 3Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma2018 · 255 citations
  4. 4PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma2019 · 39 citations
  5. 5Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma2012 · 191 citations